TAE Life Sciences (TLS) is a biotechnology company developing a combination cancer therapy based on Boron Neutron Capture Therapy (BNCT) to improve the lives of patients with aggressive, inoperable, and recurrent cancers. TLS is the only company developing small molecule and antibody therapeutics along with in-hospital neutron source to enable next-generation BNCT as a first-line treatment for patients globally.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Boronophenylalanine (BPA), Antibody Boron Conjugates (ABC™), and nanoparticles
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):